Procaps Group (NASDAQ: PROC) is a vertically integrated pharmaceutical and biotechnology company specializing in the development, manufacturing and commercialization of a broad array of prescription drugs, over-the-counter medications, nutritional supplements and cosmeceutical products. Leveraging proprietary drug‐delivery technologies, including microencapsulation, liposomal and nanoparticle platforms, Procaps Group aims to enhance the bioavailability and stability of active pharmaceutical ingredients. The company’s full‐service model spans research and development, regulatory affairs, large-scale production and distribution, enabling it to address market demands with both generic and branded offerings.
Founded in 1978 and headquartered in Caracas, Venezuela, Procaps Group has expanded its footprint across the Americas and beyond. The company operates multiple manufacturing facilities strategically located in Colombia, Brazil, Mexico, the United States and the Dominican Republic. These sites are designed to meet global regulatory standards, including U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requirements. In addition to its own product lines, Procaps Group offers contract development and manufacturing services (CDMO), providing end-to-end solutions for third-party pharmaceutical clients seeking advanced drug‐delivery systems.
Procaps Group’s product portfolio encompasses diversified therapeutic categories such as central nervous system agents, cardiovascular treatments, anti-infectives, and dermatological formulations, alongside a suite of functional foods, vitamins and nutraceuticals. The company’s research and development teams collaborate with academic institutions and industry partners to drive innovation in targeted drug delivery, sustained‐release technologies and novel combination therapies. This collaborative approach underpins Procaps Group’s ability to tailor solutions for emerging health challenges and evolving patient needs.
Under the leadership of Chief Executive Officer Juan Pablo Ospina, Procaps Group emphasizes strategic growth through geographic expansion, technology enhancement and operational excellence. The executive team includes experienced leaders in finance, quality assurance and international regulatory affairs, all focused on maintaining rigorous compliance standards and advancing sustainable practices. With a commitment to innovation, quality and global reach, Procaps Group continues to strengthen its position as a recognized partner for pharmaceutical development and manufacturing across key emerging and developed markets.
AI Generated. May Contain Errors.
Free PROC Stock Alerts